New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.05mg (additional 5% overage); salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.05mg/0.025mg per dose - active: fluticasone propionate 0.05mg (additional 5% overage) salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.125mg; salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.125mg/0.025mg per dose - active: fluticasone propionate 0.125mg salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.25mg; salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.25mg/0.025mg per dose - active: fluticasone propionate 0.25mg salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

a-s medication solutions - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol 50 ug - advair diskus is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. advair diskus should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use advair diskus is not indicated for the relief of acute bronchospasm. advair diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. advair diskus 250/50 is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. advair diskus 250/50 twice daily is the only approved dosage for the treatment of copd because an efficacy advantage of the higher strength advair diskus 500/50 over advair diskus 250/50 has not been demonstrated. important limitatio

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - asthma - drugs for obstructive airway diseases, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd

Israel - Inggeris - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 100 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.

Israel - Inggeris - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.